Agios Pharmaceuticals Inc

NASDAQ:AGIO   3:59:58 PM EDT
55.36
-0.36 (-0.65%)
Products, Regulatory

Agios Announces Final Overall Survival Data From Phase 3 ClariDHY Study Of Tibsovo In Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

Published: 09/21/2020 11:30 GMT
Agios Pharmaceuticals Inc (AGIO) - Agios Announces Final Overall Survival Data From Phase 3 Claridhy Study of Tibsovo® (ivosidenib Tablets) in Previously Treated Idh1-mutant Cholangiocarcinoma Patients.
Agios Pharmaceuticals - Consistent Trend in Improved Os Observed in Patients Treated With Tibsovo Versus Placebo, But Was Not Statistically Significant.